Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | MTOR | P42345 | 1/20 | 0.67 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.67 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.67 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.67 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.45 |
| ▸ | ALB | P02768 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10015791 | 1.00 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL399323 | 1.00 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL399324 | 1.00 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| Phosphoric Acid SCHEMBL3100818 | 0.95 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| Phosphoric Acid SCHEMBL1299876 | 0.95 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| Pyrophosphoric Acid SCHEMBL3100835 | 0.90 | LMNA (0.57) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL24337513 | 0.90 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL14929500 | 0.90 | LMNA (0.59) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10015807 | 0.90 | LMNA (0.59) | LMNATHRBMTORMDM2NCOA1 | |
| Triphosphate SCHEMBL31006154 | 0.88 | P2RY2 (0.55) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024963-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2022-01-27 | — | — | US | disclosed |
| US-20110071101-A1 | Nucleoside Phosphonate Analogs | BOOJAMRA CONSTANTINE G | 2011-03-24 | — | — | US | disclosed |
| US-20080145372-A1 | Bioreductively-Activated Prodrugs | ANGIOGENE, PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| EP-1799698-A1 | BIOREDUCTIVELY-ACTIVATED PRODRUGS | Angiogene Pharmaceuticals Limited (GB) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006032921-A1 | BIOREDUCTIVELY-ACTIVATED PRODRUGS | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024963-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NUDT1, ITPA, MTAP | LMNA 4331/4885THRB 3483/4885MTOR 779/4885 |
| US-20110071101-A1 | Nucleoside Phosphonate Analogs | TYMP, PNP, NUDT1 | LMNA 1265/4885THRB 3076/4885MTOR 1100/4885 |
| US-20080145372-A1 | Bioreductively-Activated Prodrugs | NME2, PNP, NUDT1 | LMNA 1716/4885THRB 3430/4885MTOR 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.